Vortioxetine: a New Treatment for Major Depressive Disorder

@article{Connolly2016VortioxetineAN,
  title={Vortioxetine: a New Treatment for Major Depressive Disorder},
  author={K. R. Connolly and M. Thase},
  journal={Expert Opinion on Pharmacotherapy},
  year={2016},
  volume={17},
  pages={421 - 431}
}
INTRODUCTION Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD. [...] Key Method Pre-approval studies were identified as all randomized, placebo-controlled studies of vortioxetine listed on clinicaltrials.gov.Expand
Vortioxetine: A new alternative for the treatment of major depressive disorder
TLDR
The aim of this systematic review is to describe the pharmacology, clinical efficacy and safety profile of vortioxetine, as well as its potential effectiveness in improving cognitive symptoms. Expand
Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder.
TLDR
This newly identified binding mechanism underlying vilazodone's partial agonism to the 5-HT1A receptor will provide valuable information for medicinal chemists working in the field of rational design of novel SPARIs for MDD treatment. Expand
Vortioxetine: A Review in Cognitive Dysfunction in Depression
TLDR
Vortioxetine is a useful treatment option in patients with MDD where impaired cognitive function is apparent and significantly improved a subjective measure of cognitive function (the Perceived Deficits Questionnaire) and an objective measure of functional capacity (the University of San Diego performance-based skills assessment). Expand
Vortioxetine and Lewy Body Disorders
Introduction: Vortioxetine is a newer antidepressant medication with reported potential for mitigating cognitive impairment secondary to major depressive disorder. However, the current study suggestsExpand
Vortioxetine: An antidepressant apart?
Antidepressants remain a mainstay of treatment to alleviate the heavy economic, societal and human tolls imposed by depression. Nevertheless, the high rates of treatment failure and poor adherenceExpand
Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018
TLDR
The efficacy of tranylcypromine, paroxetine, clonazepam, alprazolam and escitalopram is confirmed, and vortioxetine and TMS, with duration of 4 or more weeks, also seems to be effective. Expand
Vortioxetine: Clinical Pharmacokinetics and Drug Interactions
Vortioxetine is a novel antidepressant with multimodal activity currently approved for the treatment of major depressive disorder. Vortioxetine is orally administered once daily at 5- to 20-mg doses.Expand
Paroxetine versus Vortioxetine for Depressive Symptoms in Postmenopausal Transition: A Preliminary Study.
TLDR
This observational study aims to compare paroxetine and vortioxetine in a sample of patients affected by postmenopausal depression attending the Anxiety and Depression Clinic in terms of efficacy in determining clinical remission (HDRS ≤ 7) and tolerability; improvement of autonomic and cognitive symptoms. Expand
An open-label, flexible dose adaptive study evaluating the efficacy of vortioxetine in subjects with panic disorder
TLDR
Some support for the use of vortioxetine in the management of panic disorder is provided, with a statistically significant decrease in the occurrence of panic attacks and a moderate improvement in the quality of life. Expand
Advances in antidepressants for treating post-stroke depression
  • S. Paolucci
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2017
TLDR
This report provides an updated review about pharmacological state of art of PSD, including efficacy and safety of different drugs and their role on prevention, treatment and functional outcome. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 60 REFERENCES
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
TLDR
Overall, trazodone is an effective and well tolerated antidepressant (SARI) with an important role in the current treatment of MDD both as monotherapy and as part of a combination strategy. Expand
A Review of Vilazodone, Serotonin, and Major Depressive Disorder
TLDR
Vilazodone has demonstrated efficacy in 2 large, randomized, double-blind, placebo-controlled trials in major depressive disorder and is effective in patients with high levels of anxiety, and future studies corroborate the clinical benefits attributed to its mechanism of action. Expand
Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.
TLDR
The side-effect profile is similar to that of SSRIs, with gastrointestinal symptoms being most common, and a low incidence of sexual dysfunction and sleep disruption possibly ascribed to vortioxetine's receptor modulation. Expand
Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder.
TLDR
The results suggest that vortioxetine may be an effective treatment option for MDD, but they should be interpreted and translated into clinical practice with caution, as the meta-analysis was based on a limited number of heterogeneous RCTs. Expand
Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
TLDR
A large and significant treatment effect on the Montgomery-Asberg Depression Rating Scale and statistically significant improvement on the CGI-S demonstrated meaningful depressive symptom improvements. Expand
The US Food and Drug Administration's perspective on the new antidepressant vortioxetine.
TLDR
The issues that were important to the FDA's approval decision are emphasized, particularly the difference in the effective dose in domestic and foreign studies, and several new labeling features are noted, specifically, description of time course of treatment response and detailed sexual dysfunction evaluation. Expand
A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action
TLDR
The preclinical and clinical data suggest that trazodone acts as an antidepressant via antagonist action at 5-HT2/1C receptors, while fluoxetine likely acts as a antidepressant via inhibition of 5- HT uptake. Expand
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
TLDR
Vortioxetine demonstrated a favourable safety and tolerability profile and maintained effectiveness over 12 months of treatment, as with all open-label studies, the conclusions that can be drawn are limited by the lack of a placebo control. Expand
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
TLDR
Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs. Expand
Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.
TLDR
Vilazodone is effective for the treatment of MDD in adults, with symptom relief starting at 1 week, and is well tolerated at a dose of 40 mg/day, according to the intention-to-treat sample. Expand
...
1
2
3
4
5
...